Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus

Current Diabetes Reports

Volumn 12, Issue 3, 2012, Pages 230-238

  Abdul Ghani, Muhammad A ^a   Norton, Luke ^a   DeFronzo, Ralph A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Kidney; SGLT2 inhibition; Sodium glucose cotransport; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; IPRAGLIFLOZIN; ISIS; LX 4211; METFORMIN; PHLORIZIN; PLACEBO; REMOGLIFLOZIN; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; THIAZIDE DIURETIC AGENT; TS 071; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANTIDIABETIC ACTIVITY; ARTICLE; BALANITIS; BLADDER CANCER; BREAST CANCER; DIABETES CONTROL; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLUCOSURIA; HUMAN; HYPERGLYCEMIA; KIDNEY TUBULE ABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN FUNCTION; RENAL PROTECTION; SINGLE DRUG DOSE; URINARY TRACT INFECTION; VULVOVAGINITIS;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84861098920     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0275-6     Document Type: Article

References (60)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
3. DeFronzo RA. Banting lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-95.
4. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610-30. (Pubitemid 20169143)
5. The American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care. 2007;30(Supp I):S4-41.
6. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31:81-6.
7. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodiumglucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515-31.
8. Valtin H. Tubular reabsorption. In renal function. Boston: Little, Brown and Company; 1983.
9. Kamran M, Peterson RG, Dominguez JH. Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol. 1997;8:943-8. (Pubitemid 27427241)
10. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest. 1951;30:125-9.
11. Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, Singh P. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012;302:R75-83.
12. Chassis H, Jolliffe N, Smith H. The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine, and urea by man. J Clin Invest. 1933;12:1083-9.
13. Vick HD, Deidrich DF. Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs. Am J Physiol. 1973;224:552-7.
14. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31-8.
15. Li A, Zhang J, Greenberg J, Lee T, Liu J. Discovery of non-glucoside SGLT2 inhibitors. Bioorg Med Chem Lett. 2011;21:2472-5.
16. Bhanot S, Murray SF, Booten SL, Chakravarty K, Zanardi T, Henry S, Watts LM, Wancewicz EV, Siwkows A. ISIS 388626, an SGLT2 antisense drug, causes robust and sustained glucosuria in multiple species and is safe and well-tolerated. Diabetes. 2009;58(suppl1):A328.
17. Kahn BB, DeFronzo RA, Cushman SW, Rossetti L. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest. 1999;87:561-70.
18. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79:1510-5. (Pubitemid 17099657)
19. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest. 1987;80:1037-44. (Pubitemid 18075639)
20. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, Li Volti S, Neuhaus T, Skovby F, Swift PG, Schaub J, Klaerke D. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003;14:2873-82. (Pubitemid 37305650)
21. Oku A,UetaK,NawanoM,Arakawa K, Kano-Ishihara T, Matsumoto M, Saito A, Tsujihara K, Anai M, Asano T. Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats. Eur J Pharmacol. 2000;391:183-92. (Pubitemid 30138095)
22. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007;320:323-30. (Pubitemid 46025747)
23. Hussey E, Clark R, Amin D, Kipnes M, Semmes R, Odriscoll E, Leong J, Murphy S, Dobbins R, Nunez D. Early clinical studies to assess safety, tolerability, pharmacokinetics and pharmacodynamics of single dose of sergliflozin, a novel inhibitor of renal glucose reabsorption in healthy volunteers and subjects with type 2 diabetes mellitus. Diabetes. 2007;56(Suppl1):A189.
24. Hussey E, Dobbins R, Stolz R, Stockman N, Semmes R, Murray S, Nunez D. A double-blind randomized repeat dose study to assess safety, tolerability, pharmacokineticks and pharmacodynamics of three times daily dosing of sergliflozin, a novel inhibitor of renal glucose reabsorption in healthy overweight and obese subjects. Diabetes. 2007;56(Suppl1):A491.
25. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2008;327:268-76.
26. Dobbins RL, Kapur A, Kapitza C, O'connor-Semmes RL, Tao W, Hussey EK. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2) reduces serum glucose in type 2 diabetes mellitus (T2DM) patients. Diabetes. 2009;58 suppl 1:A573.
27. http://www.pharmaceutical-business-review.com/news/glaxosmith kline-discontinues- development-of-remogliflozin-090703.
28. http://www.fda.gov/downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAd visoryCommittee/ UCM262996.
29. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharm Ther. 2009;85:513.
30. Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Am Soc Pharmacol Exp Therapeut. 2010;38:405-14.
31. List J, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-7.
32. Ferrannini E, Ramos SJ, Tang W, Salsali A, List JF. Dapagliflozin monotherapy in T2DM patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, multicenter phase III trial. Diabetes Care. 2010;33:2217-24.
33. Wilding JPH, Norwood P, Tjoen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656-62.
34. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metabol. 2010;12:510-6.
35. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, Parikh SJ. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015-22.
36. Baily CJ, Gross JI, Yadav M, Iqbal N, Mansfield TA, List JF. Sustained efficacy of dapagliflozin when added to metformin in type 2 diabetes inadequately controlled by metformin monotherapy. Diabetologia. 2011;54(Suppl1):A146.
37. Del Prato S, Nauck M, Rohwedder K, Theuerkauf A, Langkilde AM, Parikh S. Long term efficacy and safety of ass-on dapagliflozin vs add-on glipizide in patients with type 2 diabetes mellitus inadequately controlled with metformin: 2 year results. Diabetologia. 2011;54(Suppl1):A852.
38. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K. Rothenberg PCanagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13:669-72.
39. Inagaki N, Kondo K, Iwasaki T, Maruyama N, Susuta Y, Sakai M, Kuki H. Canagliflozin, a novel inhibitor of sodium glucose cotransporter 2 (SGLT2) improves glycemic control and reduces body weight in Japanese type 2 diabetes Mellitus (T2DM). Diabetes. 2011;60(suppl):A999.
40. Rosensotck J, Arbit D, Usiskin K, Capuano G, Canovatchel W. Canagliflozin an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with type 2 diabetes (T2D) on metformin. Diabetes. 2010;59 suppl 1:A21.
41. Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, Ways K, Schwartz S. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012[ahead of print].
42. Polidori D, Zhao Y, Sha S, Canovatchel W. Canagliflozin treatment improves beta cell function in subject with type 2 diabetes. Diabetes. 2010;59 suppl 1:A176.
43. Grempler R, Thomas L, EckhardtM, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, Eickelmann P. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83-90.
44. Koiwai K, Seman L, Yamamura N, Macha S, Taniguchi A, Negishi T, Sesoko S, Dugi KA. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of BI 10773, a sodium-glucose co-transporter inhibitor (SGLT2), in Japanese healthy volunteers. Diabetes. 2010;59 suppl 1:2175PO.
45. Heise T, Seewaldt-Becker E, Macha S, Hantel S, Huber K, Pinnetti S, Seman L, Hans-Juergen W. BI 10773, a sodium-glucose cotransporter inhibitor (SGLT-2), is safe and efficacious following 4- week treatment in patients with type 2 diabetes. Diabetes. 2010;59 (suppl):629P.
46. Rosenstock J, Jelaska A, Seman L, Pinnetti S, Hantel S, Woerle HJ. Efficacy and safety of BI 10773, a new sodium glucose cotransporter-2 (SGLT-2) inhibitor, in type 2 diabetes inadequately controlled on metformin. Diabetes. 2011;60(suppl):989P.
47. Kashiwagi A, Utsuno A, Kazuta K, Yoshida S, Kageyama S. ASP1941, a novel, selective SGLT2 inhibitor, was effective and safe in Japanese healthy volunteers and patients with type 2 diabetes mellitus. Diabetes. 2010;59 suppl 1:A21.
48. Takinami A, Takinami Y, Kazuta K, Yoshida S, Utsuno A, Nagase I, Kashiwagi A. Ipragliflozin improved glycemic control with additional benefit of reduction of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus BRIGHTEN Study. Diabetologia. 2011;54(suppl):A149.
49. Freiman J, Ruff DA, Frazier KS, Combs K, Turnage A, Shadoan M, Powell D, Zambrowicz B, Brown P. LX4211, a dual SGLT2/SGLT1 inhibtor, shows rapid and significant improvements in glycemic control over 28 days in patients with type 2 diabetes (T2DM). Diabetes 2010;59(suppl 1), (late breaking abstract).
50. Seino Y, Sasaki T, Fukatsu A, Samukawa Y, Sakai S, Watanabe T. TS-071, a novel and selective SGLT2 inhibitor, improved glycemic control and decreased body weight in 12-week study of Japanese patients with type 2 diabetes mellitus. Diabetes. 2011;60(suppl): P998.
51. Nucci G, Amin NB, Wang X, Lee DS, Rusnak JM. The sodium glucose co-transported PF04971729, provides multifaced improvement in diabetic patients inadequately controlled on metformin. Diabetologia. 2011;54(suppl):A850.
52. Kadokura T, Ishikawa H, Nakajo I, Yoshida S, Utsuno A, Smulders RA, Morozumi K. The effect of renal impairment on the pharmacokinetics and urinary glucose excretion of the SGLT2 inhibitor ipragliflozin in Japanese type 2 diabetes mellitus patients. Diabetologia. 2011;54(suppl):A847.
53. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol. 1999;10:2569-76.
54. Thomson SC, Vallon V, Blantz RC. Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol. 2004;286:F8-18.
55. Noonan WT, Shapiro VM, Banks RO. Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocininduced diabetic rats. Life Sci. 2001;68:2967-77. (Pubitemid 32453264)
56. Dominguez JH, Camp K, Maianu L, Feister H, Garvey WT. Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am J Physiol. 1994;266:F283-90.
57. Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, Hirschman GH, Myers BD. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med. 1996;335:1636-42. (Pubitemid 26392728)
58. Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT, DeFronzo RA. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulindependent diabetes mellitus. N Engl J Med. 1991;324:1626-32.
59. Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, Kitamura K, Matsumoto M, Saito A. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol. 2001;132:578-86. (Pubitemid 32142370)
60. Parikh S, Johnsson K, Ptaszynska A, Schmitz B, Sugg J, List JF. Characterization of urinary tract infection in the setting of pharmacologically induced glucosuria. Diabetologia. 2011;54(suppl): A841.